• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改良格拉斯哥预后评分对胰腺癌的预后及临床意义:4629 例患者的荟萃分析。

Prognostic and clinical significance of modified glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients.

机构信息

Clinical Laboratory Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing 312000, Zhejiang, China.

出版信息

Aging (Albany NY). 2021 Jan 6;13(1):1410-1421. doi: 10.18632/aging.202357.

DOI:10.18632/aging.202357
PMID:33406501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7835027/
Abstract

In this study, we evaluated the association of modified Glasgow Prognostic Score (mGPS) with prognosis in pancreatic cancer (PC) by performing a meta-analysis. Potentially eligible studies were shortlisted by searching PubMed, Embase, Web of Science, Scopus, and the Cochrane Library. A total of 4,629 patients with PC from 25 studies were finally included in this meta-analysis. Meta-analyses were performed using a random-effects model or fixed-effect model according to heterogeneity. We pooled the hazard ratios (HRs) with 95% confidence intervals (CIs) to estimate the association between mGPS and overall survival (OS). The results showed that elevated mGPS correlated with poor OS in patients with PC (HR=1.92, 95% CI=1.60-2.30, p<0.002). In addition, subgroup analysis indicated that increased mGPS remained a significant prognostic factor irrespective of the study design, region, disease status, treatment, survival analysis, cancer type, study center, or the Newcastle-Ottawa Scale (NOS) score (all p<0.05). There was a significant correlation between higher mGPS and male gender (Odds ratio [OR]=1.30, 95% CI=1.01-1.67, p=0.038). Elevated pretreatment mGPS is a marker of poor prognosis in patients with PC. As an easily available and cost-effective inflammatory parameter, mGPS can serve as a promising tool for prognostication in PC.

摘要

在这项研究中,我们通过荟萃分析评估了改良格拉斯哥预后评分(mGPS)与胰腺癌(PC)预后的相关性。通过搜索 PubMed、Embase、Web of Science、Scopus 和 Cochrane Library,对潜在符合条件的研究进行了筛选。最终共有 25 项研究的 4629 名 PC 患者纳入本荟萃分析。根据异质性,使用随机效应模型或固定效应模型进行荟萃分析。我们使用合并危险比(HR)和 95%置信区间(CI)来估计 mGPS 与总生存期(OS)之间的相关性。结果表明,mGPS 升高与 PC 患者的 OS 不良相关(HR=1.92,95%CI=1.60-2.30,p<0.002)。此外,亚组分析表明,升高的 mGPS 仍然是一个显著的预后因素,无论研究设计、地区、疾病状态、治疗、生存分析、癌症类型、研究中心或纽卡斯尔-渥太华量表(NOS)评分(均 p<0.05)。较高的 mGPS 与男性性别之间存在显著相关性(优势比[OR]=1.30,95%CI=1.01-1.67,p=0.038)。治疗前 mGPS 升高是 PC 患者预后不良的标志。作为一种易于获得且具有成本效益的炎症参数,mGPS 可以作为 PC 预后的一种有前途的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/937bad3b85e1/aging-13-202357-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/7cc623479d16/aging-13-202357-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/8b4866e7638c/aging-13-202357-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/dc815f01359c/aging-13-202357-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/0fb435954533/aging-13-202357-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/937bad3b85e1/aging-13-202357-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/7cc623479d16/aging-13-202357-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/8b4866e7638c/aging-13-202357-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/dc815f01359c/aging-13-202357-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/0fb435954533/aging-13-202357-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bece/7835027/937bad3b85e1/aging-13-202357-g005.jpg

相似文献

1
Prognostic and clinical significance of modified glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients.改良格拉斯哥预后评分对胰腺癌的预后及临床意义:4629 例患者的荟萃分析。
Aging (Albany NY). 2021 Jan 6;13(1):1410-1421. doi: 10.18632/aging.202357.
2
Prognostic Significance of the Modified Glasgow Prognostic Score in Patients With Pancreatic Cancer: A Meta-Analysis.改良格拉斯哥预后评分在胰腺癌患者中的预后意义:一项荟萃分析
Dose Response. 2020 Aug 3;18(3):1559325820942065. doi: 10.1177/1559325820942065. eCollection 2020 Jul-Sep.
3
The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis.改良格拉斯哥预后评分在胰腺癌中的预后价值:一项荟萃分析。
Cancer Cell Int. 2020 Sep 22;20:462. doi: 10.1186/s12935-020-01558-4. eCollection 2020.
4
The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis.改良格拉斯哥预后评分对食管鳞癌患者预后价值的 Meta 分析。
Nutr Cancer. 2020;72(7):1146-1154. doi: 10.1080/01635581.2019.1677925. Epub 2019 Oct 16.
5
A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis.高格拉斯哥预后评分(GPS)或改良的格拉斯哥预后评分(mGPS)可预测妇科恶性肿瘤的不良预后:系统评价和荟萃分析。
Arch Gynecol Obstet. 2020 Jun;301(6):1543-1551. doi: 10.1007/s00404-020-05581-8. Epub 2020 May 14.
6
Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis.格拉斯哥预后评分或改良格拉斯哥预后评分对接受不同治疗的结直肠癌患者的预后价值:一项系统评价和荟萃分析
Cell Physiol Biochem. 2018;51(3):1237-1249. doi: 10.1159/000495500. Epub 2018 Nov 27.
7
Evaluation of Modified Glasgow Prognostic Score for Pancreatic Cancer: A Retrospective Cohort Study.胰腺癌改良格拉斯哥预后评分的评估:一项回顾性队列研究。
Pancreas. 2016 Feb;45(2):211-7. doi: 10.1097/MPA.0000000000000446.
8
Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis.改良格拉斯哥预后评分在肺癌中的临床应用:一项荟萃分析。
PLoS One. 2017 Sep 8;12(9):e0184412. doi: 10.1371/journal.pone.0184412. eCollection 2017.
9
Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.治疗前格拉斯哥预后评分和改良格拉斯哥预后评分可能是泌尿系统癌症潜在的预后生物标志物:一项系统评价和荟萃分析。
Ann Transl Med. 2019 Oct;7(20):531. doi: 10.21037/atm.2019.09.160.
10
The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.术前敏感改良格拉斯哥预后评分在预测食管鳞状细胞癌长期生存方面优于改良格拉斯哥预后评分。
Oncotarget. 2016 Oct 11;7(41):67485-67494. doi: 10.18632/oncotarget.11268.

引用本文的文献

1
The Prognostic Value of the EASIX Score in Patients with Metastatic Pancreatic Cancer.EASIX评分在转移性胰腺癌患者中的预后价值
Diagnostics (Basel). 2025 Jul 9;15(14):1740. doi: 10.3390/diagnostics15141740.
2
Global research trends and hotspots in prognostic prediction models for pancreatic cancer: a bibliometric analysis.胰腺癌预后预测模型的全球研究趋势与热点:一项文献计量分析
Front Oncol. 2025 Jul 10;15:1588735. doi: 10.3389/fonc.2025.1588735. eCollection 2025.
3
Impact of Nutritional Changes on the Prognosis in Pancreatic Cancer Patients Underwent Curative Surgery After Neoadjuvant Chemotherapy.

本文引用的文献

1
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.转移性胰腺癌中,吉西他滨+白蛋白紫杉醇治疗后采用改良 FOLFIRINOX 作为二线治疗。
BMC Cancer. 2020 May 20;20(1):449. doi: 10.1186/s12885-020-06945-8.
2
A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis.高格拉斯哥预后评分(GPS)或改良的格拉斯哥预后评分(mGPS)可预测妇科恶性肿瘤的不良预后:系统评价和荟萃分析。
Arch Gynecol Obstet. 2020 Jun;301(6):1543-1551. doi: 10.1007/s00404-020-05581-8. Epub 2020 May 14.
3
营养变化对新辅助化疗后接受根治性手术的胰腺癌患者预后的影响
Nutrients. 2025 Feb 11;17(4):647. doi: 10.3390/nu17040647.
4
Tocilizumab in combination with corticosteroids: potential for managing cancer cachexia with systemic hyperinflammation.托珠单抗联合皮质类固醇:治疗伴有全身炎症的癌症恶病质的潜力。
Front Immunol. 2024 Dec 5;15:1477310. doi: 10.3389/fimmu.2024.1477310. eCollection 2024.
5
Cachexia-Affected Survival Based on Inflammatory Parameters Compared to Complex Conventional Nutritional Assessments in Patients with Pancreatic Cancer and Other Gastrointestinal Tumors-The CONKO 020 Investigation.基于炎症参数的恶病质相关生存情况与胰腺癌及其他胃肠道肿瘤患者复杂传统营养评估的比较——CONKO 020研究
Cancers (Basel). 2024 Mar 18;16(6):1194. doi: 10.3390/cancers16061194.
6
Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy.炎症和免疫系统对肝癌切除术后复发的影响。
Cancer Med. 2024 Feb;13(4):e7018. doi: 10.1002/cam4.7018.
7
Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study.肺大细胞神经内分泌癌的预后评分:一项回顾性队列研究。
Heliyon. 2024 Jan 24;10(3):e25029. doi: 10.1016/j.heliyon.2024.e25029. eCollection 2024 Feb 15.
8
Comparison of three nutritional assessment methods associated with the prognostic impact of laryngeal cancer.三种营养评估方法与喉癌预后影响的比较。
Support Care Cancer. 2023 Dec 2;31(12):737. doi: 10.1007/s00520-023-08148-w.
9
Pretreatment Modified Glasgow Prognostic Score for Predicting Prognosis and Survival in Elderly Patients with Gastric Cancer Treated with Perioperative FLOT.术前改良格拉斯哥预后评分预测接受围手术期 FLOT 治疗的老年胃癌患者的预后和生存。
Nutrients. 2023 Sep 26;15(19):4156. doi: 10.3390/nu15194156.
10
Hospital volume and prognosis of patients with metastatic pancreatic cancer: A study using the Osaka Cancer Registry.转移性胰腺癌患者的医院诊疗量与预后:一项基于大阪癌症登记处的研究
J Cancer Res Clin Oncol. 2023 Nov;149(14):12835-12841. doi: 10.1007/s00432-023-04966-x. Epub 2023 Jul 18.
C-reactive Protein Is a Predictor of Prognosis of Prostate Cancer: A Systematic Review and Meta-Analysis.
C-反应蛋白是前列腺癌预后的预测因子:系统评价和荟萃分析。
Ann Clin Lab Sci. 2020 Mar;50(2):161-171.
4
The prevalence of cancer associated systemic inflammation: Implications of prognostic studies using the Glasgow Prognostic Score.癌症相关全身炎症的流行:使用格拉斯哥预后评分的预后研究的意义。
Crit Rev Oncol Hematol. 2020 Jun;150:102962. doi: 10.1016/j.critrevonc.2020.102962. Epub 2020 Apr 18.
5
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.治疗前格拉斯哥预后评分和改良格拉斯哥预后评分可能是泌尿系统癌症潜在的预后生物标志物:一项系统评价和荟萃分析。
Ann Transl Med. 2019 Oct;7(20):531. doi: 10.21037/atm.2019.09.160.
7
New therapeutic targets in pancreatic cancer.胰腺癌的新治疗靶点。
Cancer Treat Rev. 2019 Dec;81:101926. doi: 10.1016/j.ctrv.2019.101926. Epub 2019 Nov 11.
8
Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute.改良格拉斯哥预后评分作为广泛期小细胞肺癌患者的预后因素:单中心回顾性研究。
Chemotherapy. 2019;64(3):129-137. doi: 10.1159/000502681. Epub 2019 Oct 17.
9
The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis.改良格拉斯哥预后评分对食管鳞癌患者预后价值的 Meta 分析。
Nutr Cancer. 2020;72(7):1146-1154. doi: 10.1080/01635581.2019.1677925. Epub 2019 Oct 16.
10
Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.中性粒细胞与淋巴细胞比值对新辅助放化疗后手术切除的边界可切除胰腺导管腺癌的预后影响。
World J Surg. 2019 Dec;43(12):3153-3160. doi: 10.1007/s00268-019-05159-9.